ProtoKinetix, Incorporated Stock Other OTC
Equities
PKTX
US7437221002
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 6.58M 8.95M |
---|---|---|---|---|---|
Net income 2022 | -1M -1.36M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 25.55K 34.77K | Net cash position 2023 | 20.41K 27.78K | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.29
x | P/E ratio 2023 |
-1.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.74% |
Managers | Title | Age | Since |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Michael Guzzetta
DFI | Director of Finance/CFO | 66 | 17-11-13 |
Victoria Bantz
LAW | General Counsel | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Edward McDonough
BRD | Director/Board Member | 71 | 15-06-30 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |